pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Endocrinology & Metabolism · news · pharmadog
← back to Endocrinology & Metabolism
News · Endocrinology & Metabolism
226
stories
May 12, 26
Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanoma
onclive
May 12, 26
Supreme Court extends mifepristone deadline
stat
May 12, 26
Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk
onclive
May 12, 26
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
onclive
May 12, 26
Unmet Needs in Endometrial Cancer
onclive
May 12, 26
EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs
onclive
May 12, 26
Future Directions in Relapsed and Refractory Multiple Myeloma
onclive
May 12, 26
Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer
onclive
May 12, 26
Sequencing Strategies After Progression in Multiple Myeloma
onclive
May 12, 26
EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy
onclive
May 12, 26
Sequencing ADCs in Endometrial Cancer
onclive
May 12, 26
Second Clinical Scenario - Progressive Disease Despite Hematocrit Control
onclive
May 12, 26
PCOS’s new name is PMOS, a small letter change that required a big scientific process
stat
May 12, 26
6 takeaways from STAT’s investigation into the U.S. alcohol epidemic
stat
May 11, 26
Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
onclive
May 11, 26
MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
onclive
May 11, 26
Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT
onclive
May 11, 26
Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection
onclive
May 11, 26
Expanding ctDNA Applications to RCC and Germ Cell Tumors
onclive
May 11, 26
RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice
onclive
May 11, 26
ctDNA in Metastatic Urothelial Carcinoma
onclive
May 11, 26
Institutional Perspectives on Treatment Thresholds in PLGG
onclive
May 11, 26
Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups
onclive
May 10, 26
Five Under 5: Top Oncology Videos for the Week of 5/3
onclive
May 9, 26
The OncFive: Top Oncology Articles for the Week of 5/3
onclive
May 8, 26
Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT
onclive
May 8, 26
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
onclive
May 8, 26
Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
onclive
May 8, 26
Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
onclive
May 8, 26
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
onclive
← prev
page 6 of 8
next →
